Ocrelizumab

Commodity a leaf — nothing below it, 8 links to KBLI

Level: Commodity
Parent: 51202500
Below: 0
Links · KBLI: 8

Definition

UNSPSC 51202506

Ocrelizumab is a pharmaceutical drug for the treatment of multiple sclerosis (MS). It is a humanized anti-CD20 monoclonal antibody. It targets CD20 marker on B lymphocytes and hence is an immunosuppressive drug. Ocrelizumab binds to an epitope that overlaps with the epitope to which rituximab binds.

Same parent

Under 51202500 · 6

51202501 Leflunomide Commodity 51202502 Mizoribine Commodity 51202503 Procodazole Commodity 51202504 Procodazole ethyl ester Commodity 51202505 Procodazole sodium Commodity 51202506 Ocrelizumab You are here

Activities that produce or sell this

KBLI · 8

Inherited from family 51200000.

21012 Industri Produk Farmasi untuk Manusia Sub-class 21013 Industri Produk Farmasi untuk Hewan Sub-class 46441 Perdagangan Besar Sediaan Farmasi untuk Manusia Sub-class 46442 Perdagangan Besar Sediaan Farmasi untuk Hewan Sub-class 46902 Perdagangan Besar Berbagai Macam Barang Selain di Grosir/Perkulakan Swalayan Sub-class 47721 Perdagangan Eceran Sediaan Farmasi untuk Manusia di Apotek Sub-class 47722 Perdagangan Eceran Sediaan Farmasi untuk Manusia Selain di Apotek Sub-class 47726 Perdagangan Eceran Obat Farmasi untuk Hewan Sub-class

Warning
The links were generated with a large language model (Gemini 3.5 Flash), matching UNSPSC at the family level to KBLI at the kelompok level. Some of them maybe are wrong, so check any link you intend to rely on.